MTOR inhibitor-related pulmonary toxicity; Incidence even higher

Acta Oncologica

Volumn 52, Issue 6, 2013, Pages 1234-

  Willemsen, Anna E C A B ^a   Van Herpen, Carla M L ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PLACEBO;

AWARENESS; CANCER CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; INCIDENCE; LETTER; LUNG DISEASE; META ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RISK; CONTROLLED STUDY; HIGH RISK PATIENT; LUNG TOXICITY; RISK FACTOR; SENSITIVITY ANALYSIS;

EID: 84983122369     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2013.770166     Document Type: Letter

References (10)

1. Iacovelli R, Palazzo A, Mezi S, Morano F, Naso G, Cortesi E. Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials. Acta Oncol 2012; 51: 873-9.
2. Motzer RJ, Escudier B, Oudard S, Hutson T E, Porta C, Bracarda S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Cancer 2010; 116: 4256-65.
3. Ellard S L, Clemons M, Gelmon K A, Norris B, Kennecke H, Chia S, et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 2009; 27: 4536-41.
4. Amato R J, Jac J, Giessinger S, Saxena S, Willis J P. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 2009; 115: 2438-46.
5. White DA, Schwartz LH, Dimitrijevic S, Scala LD, Hayes W, Gross SH. Characterization of pneumonitis in patients with advanced non-small cell lung cancer treated with everolimus (RAD001). J Thorac Oncol 2009; 4: 1357-63.
6. Duran I, Siu L L, Oza AM, Chung TB, Sturgeon J, Townsley C A, et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 2006; 42: 1875-80.
7. Maroto JP, Hudes G, Dutcher JP, Logan TF, White CS, Krygowski M, et al. Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. J Clin Oncol 2011; 29: 1750-6.
8. White DA, Camus P, Endo M, Escudier B, Calvo E, Akaza H, et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 2010; 182: 396-403.
9. Dabydeen DA, Jagannathan JP, Ramaiya N, Krajewski K, Schutz FA, Cho DC, et al. Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: Incidence, radiographic fi ndings and correlation with clinical outcome. Eur J Cancer 2012; 48: 1519-24.
10. Bellmunt J, Szczylik C, Feingold J, Strahs A, Berkenblit A. Temsirolimus safety profi le and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 2008; 19: 1387-92.